Radionuclide Injection Market By Product / Radiopharmaceutical Type (Diagnostic Radiopharmaceuticals [SPECT Tracers, PET Tracers], Therapeutic Radiopharmaceuticals [Targeted Radionuclide Therapy, Radioligand Therapy]); By Application / Indication (Oncology [Prostate Cancer, Neuroendocrine Tumors, Thyroid Cancer, Lymphoma, Breast Cancer, Metastatic Bone Disease], Cardiology [Myocardial Perfusion Imaging, Coronary Artery Disease Assessment], Neurology and Neuroendocrinology [Brain Perfusion Imaging, Epilepsy Mapping, Dementia Evaluation], Other Indications [Nephrology, Gastroenterology, Skeletal Imaging, Selected Inflammatory Conditions]); By End User (Hospitals and Clinics, Diagnostic Imaging and Outpatient Centers, Academic and Research Institutes); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

Radionuclide Injection Market: PET Diagnostics and Radioligand Therapy Set the Pace – (Updated On: 1st-Oct-2026)

The Global Radionuclide Injection Market was estimated at USD 416.72 million in 2025 and is projected to reach USD 777.24 million by 2032, expanding at a CAGR of 9.31% during 2026–2032.

 

Radionuclide injections are radioactive pharmaceutical preparations administered intravenously for diagnostic imaging or targeted radionuclide therapy. Injectable products using isotopes such as fluorine-18 and lutetium-177 are commercially important across PET imaging and radioligand therapy.

 

The clinical base for injectable radiopharmaceuticals is substantial. More than 50 million nuclear medicine procedures are performed annually worldwide, and approximately 90% are diagnostic procedures. More than 10,000 hospitals worldwide use radioisotopes in medicine, creating an established delivery network for diagnostic and therapeutic radiopharmaceuticals. These procedure figures represent the broader nuclear-medicine base rather than injection volumes alone, as not every nuclear medicine procedure uses an injectable product.

 

Therapeutic radionuclide injections are generating significant pharmaceutical revenue. Novartis' Pluvicto, a lutetium-177 radioligand therapy administered intravenously, generated USD 1.994 billion in 2025 sales, increasing 43% from 2024. Lutathera, another lutetium-177 radiopharmaceutical administered by intravenous infusion, generated USD 816 million in 2025, up 13% year over year. Together, the two products generated approximately USD 2.81 billion, demonstrating the commercial scale being reached by injectable radionuclide therapies in oncology.

 

Diagnostic radionuclide injections also represent a substantial commercial segment. Lantheus' PYLARIFY (piflufolastat F-18) injection is an intravenous radioactive diagnostic agent used for PET imaging of PSMA-positive lesions in prostate cancer. PYLARIFY generated USD 989.1 million in 2025 revenue. Its prescribing information specifies administration as a bolus intravenous injection, making the product directly applicable to the radionuclide injection market.

 

Product development is also expanding the injectable diagnostic base. In March 2026, the U.S. FDA approved Lantheus' PYLARIFY TruVu, a new formulation of piflufolastat F-18 injection for PSMA PET imaging. Lantheus stated that the formulation is designed to support larger production batches and greater patient availability, with a phased U.S. launch planned for the fourth quarter of 2026.

 

The most directly measurable commercial activity in the Radionuclide Injection Market is therefore concentrated in F-18 PET diagnostic injections and Lu-177 therapeutic injections. Products such as PYLARIFY, Pluvicto, and Lutathera provide direct evidence of demand for intravenously administered radiopharmaceuticals across prostate cancer imaging and targeted oncology treatment.

 

Segment Leadership and High-Growth Revenue Pockets

By Product Type – Diagnostic Scale Meets Rapid Therapeutic Expansion

Leading Subsegment – Diagnostic Radiopharmaceuticals

Diagnostic radiopharmaceuticals accounted for approximately 65% of the Radionuclide Injection Market in 2025, generating nearly USD 270.87 million, and are projected to reach about USD 449.38 million by 2032, expanding at a CAGR of 7.50% during 2026–2032. These injectable agents use radionuclides that emit gamma rays or positrons, enabling PET and SPECT imaging to assess organ function, detect metabolic abnormalities, identify cancers and cardiovascular or neurological disorders, and determine patient eligibility for targeted radionuclide therapies based on specific molecular markers.

Fastest-Growing Subsegment – Therapeutic Radiopharmaceuticals

Therapeutic radiopharmaceuticals accounted for approximately 35% of Radionuclide Injection Market revenue in 2025, equivalent to USD 145.85 million, and are projected to grow at the fastest CAGR of 12.27% during 2026–2032, reaching nearly USD 327.91 million by 2032. Growth is driven by increasing use of injectable targeted radionuclide therapies in prostate cancer, neuroendocrine tumors, thyroid cancer, and bone metastases, where radioactive isotopes deliver localized cytotoxic radiation while limiting exposure to surrounding healthy tissue and enabling treatment of disseminated metastatic disease.

 

By Application – Oncology Controls Both Scale and Growth

Leading and Fastest-Growing Subsegment – Oncology

Oncology accounted for approximately 58% of the Radionuclide Injection Market in 2025, generating nearly USD 241.70 million, and is projected to reach about USD 488.04 million by 2032 at a CAGR of 10.56%. Growth is driven by increasing use of targeted radionuclide injections in prostate cancer, neuroendocrine tumors, thyroid cancer, and bone metastases. Expanding adoption of theranostic approaches, including Lutetium-177-, Gallium-68-, and Radium-223-based therapies, is strengthening clinical demand for precision cancer imaging and systemic radiopharmaceutical treatment.

 

By End User – Hospitals Retain Control While Outpatient Imaging Expands

Leading Subsegment – Hospitals and Clinics

Hospitals and clinics dominated the Radionuclide Injection Market with approximately 62% of global revenue in 2025, generating nearly USD 258.37 million, and are projected to reach about USD 467.77 million by 2032 at a CAGR of 8.85%. Their leadership is driven by specialized nuclear medicine infrastructure, including hot labs, radiation-shielded storage, dose preparation, and multidisciplinary teams of nuclear medicine physicians, physicists, technologists, and nurses required for the safe handling and administration of diagnostic and therapeutic radionuclide injections.

Fastest-Growing Subsegment – Diagnostic Imaging and Outpatient Centers

Diagnostic imaging and outpatient centers accounted for approximately 28% of the Radionuclide Injection Market in 2025, generating USD 116.68 million, and are projected to expand at the fastest end-user CAGR of 10.90% during 2026–2032, reaching nearly USD 240.73 million by 2032. Growth is supported by increasing PET/CT and SPECT/CT procedures, wider use of Technetium-99m and Fluorine-18 tracers, and greater outpatient delivery of nuclear medicine diagnostics requiring controlled radiopharmaceutical preparation, dosing, administration, and radiation-safety infrastructure.

 

By Geography – North America Leads Revenue While Asia-Pacific Adds Capacity Fastest

Leading Subsegment – North America

North America accounted for approximately 44% of global Radionuclide Injection Market revenue in 2025, equivalent to USD 183.36 million. The regional market is projected to expand at an 8.70% CAGR during 2026–2032, reaching nearly USD 328.78 million by 2032. Growth is being reinforced by the wider adoption of targeted radionuclide injections in oncology, where their role has expanded beyond diagnostic applications toward precision treatment, supported by increasing clinical use of radiopharmaceutical therapies and advanced nuclear medicine infrastructure across major centers.

Fastest-Growing Subsegment – Asia-Pacific

Asia-Pacific accounted for approximately 22% of the Radionuclide Injection Market in 2025, representing revenue of about USD 91.68 million. The region is projected to expand at the fastest CAGR of 11.34% during 2026–2032, with market revenue reaching nearly USD 194.46 million by 2032. Growth is supported by rising cancer incidence, wider adoption of nuclear medicine procedures, expanding clinical research activity, and increasing investment in precision diagnostics and targeted radionuclide therapies across major Asia-Pacific healthcare markets, including China, Japan, and India.

 

Competitive Landscape: Radioligand Therapies, PET Diagnostics and Distribution Scale Shape Market Leadership

Novartis

Novartis is a leading participant in therapeutic radionuclide injections, particularly through Pluvicto (lutetium-177 vipivotide tetraxetan) for prostate cancer and Lutathera (lutetium-177 dotatate) for neuroendocrine tumors. Pluvicto generated USD 1.994 billion in 2025 sales, increasing 43% year over year, while Lutathera generated another USD 816 million, up 13%. Combined sales of these two radioligand therapies exceeded USD 2.8 billion in 2025. Pluvicto's commercial reach also expanded during 2025, with its post-taxane prostate cancer indication approved in 32 countries, while earlier-line approvals were secured in markets including the United States, Japan, and China. The portfolio places Novartis at the center of the shift toward higher-value targeted radionuclide therapy.

Curium

Curium has one of the broadest operating footprints in nuclear medicine, combining isotope processing, radiopharmaceutical manufacturing, radiopharmacy operations, and distribution. The company reports more than EUR 1 billion in annual revenue in 2025, along with a portfolio exceeding 50 radiopharmaceutical products. Curium serves approximately 14 million patients annually, works with more than 6,000 customers, and supplies markets across 60+ countries. Its network includes manufacturing operations and more than 40 radiopharmacies, giving the company substantial exposure to both high-volume diagnostic nuclear medicine and expanding therapeutic applications. Its current development focus includes prostate cancer and neuroendocrine tumors.

Lantheus

Lantheus holds a strong position in PET-based precision diagnostics, particularly prostate cancer imaging. The company generated approximately USD 1.54 billion in worldwide revenue during 2025, with PYLARIFY alone contributing USD 989.1 million. PYLARIFY is a PSMA-targeted PET imaging agent used to identify prostate cancer lesions and accounted for a substantial portion of Lantheus' commercial radiopharmaceutical business. The company also expanded its platform through the acquisitions of Life Molecular Imaging and Evergreen Theragnostics during 2025. Lantheus has subsequently increased its strategic focus on PET radiodiagnostics, giving it an important position where radionuclide injections support patient selection, disease staging, treatment planning, and theranostic pathways.

Other Companies and Their Roles

• Cardinal Health: Operates a large U.S. nuclear-pharmacy and PET manufacturing network, including 130+ radiopharmacies and 30+ PET manufacturing centers, supporting distribution of SPECT and PET radiopharmaceutical doses to hospitals and imaging centers.

• Jubilant Radiopharma: Develops, manufactures, and distributes diagnostic and therapeutic radiopharmaceuticals and operates a major U.S. radiopharmacy network serving hospitals, cardiology practices, and imaging centers.

• Telix Pharmaceuticals: Participates in prostate cancer imaging through Illuccix and Gozellix, both based on gallium-68 PSMA targeting, while developing a broader diagnostic and therapeutic radiopharmaceutical portfolio.

• Bayer: Maintains a therapeutic radionuclide position through Xofigo (radium-223 dichloride) for castration-resistant prostate cancer with symptomatic bone metastases.

• Bracco: Supplies diagnostic nuclear-medicine products including CardioGen-82, a rubidium-82 PET solution used in cardiac imaging, alongside other nuclear-medicine imaging products.

 

Analyst Outlook: Radioligand Growth Meets Next-Generation Isotopes

The radionuclide injection market is progressing from high-volume diagnostic nuclear medicine toward a more balanced model that combines PET/SPECT imaging with targeted radioligand therapy. The strongest growth opportunities are emerging around lutetium-177 therapies, PSMA-targeted prostate cancer treatment, neuroendocrine tumor management, expanded PET tracer availability, and next-generation isotopes such as actinium-225.

 

Radionuclide Injection Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 416.72 Million
Revenue Forecast in 2032	USD 777.24 Million
Overall Growth Rate	CAGR of 9.31% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product / Radiopharmaceutical Type, By Application / Indication, By End User, By Geography
By Product / Radiopharmaceutical Type	Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals
By Application / Indication	Oncology, Cardiology, Neurology and Neuroendocrinology, Other Indications
By End User	Hospitals and Clinics, Diagnostic Imaging and Outpatient Centers, Academic and Research Institutes
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Germany, Belgium, France, Italy, Spain, UK, China, Japan, India, South Korea, Australia, Brazil, Mexico, Argentina, Turkey, South Africa
Market Drivers	Growing nuclear medicine procedure volumes, rising adoption of targeted radionuclide therapy, increasing use of PET and SPECT imaging, expanding oncology applications, development of radioligand therapies, and investment in nuclear-medicine and radiopharmaceutical infrastructure
Customization Option	Available upon request